¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reverse transcriptase polymerase chain reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • cessation reaction
    Á¤Áö¹ÝÀÀ
  • cholera red reaction
    ÄÝ·¹¶óÀû»ö¹ÝÀÀ
  • defensive reaction
    ¹æ¾îÀÛ¿ë
  • drug reaction
    ¾à¹°¹ÝÀÀ
  • dystonic reaction
    ±äÀåÀÌ»ó¹ÝÀÀ
  • delayed allergic reaction
    Áö¿¬¾Ë·¹¸£±â¹ÝÀÀ
  • delayed cell-mediated reaction
    Áö¿¬¼¼Æ÷¸Å°³¹ÝÀÀ
  • delayed hemolytic transfusion reaction
    Áö¿¬¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • delayed reaction
    Áö¿¬¹ÝÀÀ
  • depressive reaction
    ¿ì¿ï¹ÝÀÀ
  • dissociative reaction
    ÇØ¸®¹ÝÀÀ
  • donor reaction
    Á¦°øÀÚ¹ÝÀÀ, °ø¿©ÀÚ¹ÝÀÀ
  • dopa reaction
    µµÆÄ¹ÝÀÀ
  • downgrading reaction
    ÇÏÇâ¹ÝÀÀ
  • exergonic reaction
    ¿¡³ÊÁö¹æÃâ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • counter reaction
    ¿ª¹ÝÀÀ
  • coupled reaction
    °ø¿ª¹ÝÀÀ, ¦Áø¹ÝÀÀ, ¿¬°á¹ÝÀÀ
  • cross reaction
    ±³Â÷¹ÝÀÀ
  • cutaneous reaction
    ÇǺιÝÀÀ
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cytotoxic reaction
    µ¶¼º¹ÝÀÀ, ¼¼Æ÷µ¶¼º¹ÝÀÀ
  • reaction center
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
  • defensive reaction
    ¹æ¾îÀÛ¿ë
  • deficient release reaction
    ¹æÃâ¹ÝÀÀ°áÇÌ
  • delayed reaction
    Áö¿¬¹ÝÀÀ
  • delayed allergic reaction
    Áö¿¬¾Ë·¹¸£±â¹ÝÀÀ
  • delayed cell-mediated reaction
    Áö¿¬¼¼Æ÷¸Å°³¹ÝÀÀ
  • delayed hemolytic transfusion reaction
    Áö¿¬¿ëÇ÷¼öÇ÷ºÎÀÛ¿ë
  • depressive reaction
    ¿ì¿ï¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • general reaction
    Àü½Å¹ÝÀÀ.
  • gluteal reaction
    µÐ ¹ÝÀÀ(ÔëÚãëì).
  • gold reaction
    ±Ý¹ÝÀÀ.
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • grief reaction
    ¾Öµµ<ºñ¾Ö>¹ÝÀÀ(äîÓú<Ýèäî>Úãëë)
  • gross stress reaction
    ´ëÀÚ±Ø<ÃÑüÀû½ºÆ®·¹½º>¹ÝÀÀ(ÓÞí©Ð½<õÅô÷îÜ~>Úãëë)
  • group reaction
    Áý´Ü¹ÝÀÀ(̤ËÀËÑËô).
  • heat of reaction
    ¹ÝÀÀ¿­(Úãëëæð).
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemoclastic reaction
    Ç÷±¸ºØ±«¹ÝÀÀ.
  • hemolytic transfusion reaction
    ¿ëÇ÷¼º ¼öÇ÷¹ÝÀÀ.
  • heterogeneous reaction
    ºÒ±ÕÀϹÝÀÀ, ºÒ±ÕÁú¹ÝÀÀ.
  • heterophil(e) antibody reaction
    ÀÌÁ¾Ä£È­(¼º) Ç×ü¹ÝÀÀ(¡­Úãëë).
  • homograft reaction
    µ¿Á¾ÀÌ½ÄÆí¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • reverberating chain
    ¹ÝÇâ(ÚãúÂ)»ç½½.
  • side chain
    Ãø¼â, °ç°¡Áö, °ç»ç½½.
  • side chain isomerism
    Ãø¼âÀ̼º(ö°áðì¶àõ).
  • side chain theory
    Ç×ü»ý»êÃø¼â¼³
  • straight chain molecule
    °ðÀº»ç½½ºÐÀÚ.
  • sympathetic chain
    ±³°¨½Å°æ»ç½½
  • sympathetic ganglion chain
    ±³°¨½Å°æÀý¿¬¼â(¡­ææáð).
  • acrosome reaction
    ֟ ¹ÝÀÀ
  • activator reaction
    Ȱ¼ºÈ­¹ÝÀÀ.
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ(¡­Ñ¢Úãëë)
  • addition reaction
    ºÎ°¡¹ÝÀÀ.
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse reaction
    À¯ÇØ(êóúª)¹ÝÀÀ, ¿ª(æ½)¹ÝÀÀ.
  • aerobic reaction
    È£±â¼º ¹ÝÀÀ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Berthelot reaction
    º£¸£ÅÐ·Ô ¹ÝÀÀ(Úãëë)
  • Bial's reaction
    ºñ¾Ë ¹ÝÀÀ(Úãëë)
  • bimolecular reaction
    À̺ÐÀÚ ¹ÝÀÀ(ì£ÝÂí­Úãëë)
  • bireactant reaction
    µÎ ¹ÝÀÀ¹°(ÚãëëÚª) ¹ÝÀÀ(Úãëë)
  • bisubstrate reaction
    µÎ ±âÁú(Ðñòõ) ¹ÝÀÀ(Úãëë)
  • biuret reaction
    ºß·¿ ¹ÝÀÀ(Úãëë)
  • capsule swelling reaction
    ĸ½¶ ÆØÃ¢¹ÝÀÀ(ø³óìÚãëë)
  • Carr-Price reaction
    Ä«¸£-ÇÁ¶óÀ̽º ¹ÝÀÀ(Úãëë)
  • chemical reaction
    È­ÇйÝÀÀ(ûùùÊÚãëë)
  • complement binding reaction
    º¸Ã¼°íÁ¤ ¹ÝÀÀ(ÜÍô÷ͳïÒÚãëë)
  • concerted reaction
    Çùµ¿¹ÝÀÀ(úðÔÒÚãëë)
  • cross-reaction
    ±³Â÷¹ÝÀÀ(Îßó©Úãëë)
  • cyanogen bromide reaction
    ºê·ÒÈ­ ½Ã¾È ¹ÝÀÀ(Úãëë)
  • cycloaddition reaction
    °í¸® ÷°¡¹ÝÀÀÈ­(ôÕÊ¥Úãëëûù)
  • dark reaction
    ¾Ï¹ÝÀÀ(äÞÚãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
WFR Weil-Felix reaction; wheal-and-flare reaction
WR Wassermann reaction; water retention; weakly reactive; weak response; whole response; wiping reactio...
rT3 reverse T3
rev reverse; review; revolution
RO radiation oncology; radiation output; ratio of; relative odds; renal osteodystrophy; reverse osmosis...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PCR DNA-polymerase chain reaction
DD-PCR Differential display polymerase chain reaction
DPCR Differential polymerase chain reaction
ISPCR i situ polymerase chain reaction
IPCR Inverse polymerase chain reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nitroso- ´ÏÆ®·Î¼Ò ¶Ç´Â ´ÏÆ®·Î½ÇÀ» ÇÔÀ¯Çϰí ÀÖÀ½À» ³ªÅ¸³»´Â Á¢µÎ¾î.

    nitrosoindol reaction

    ´ÏÆ®·Î Àε¹ ¹ÝÀÀ
  • nociceptive reaction
    Ä§ÇØ ¹ÝÀÀ
  • nonspecific reaction
    ºñƯÀÌ ¹ÝÀÀ
  • order of reaction
    ¹ÝÀÀ Â÷¼ö
  • overanxious reaction
    °úºÒ¾È ¹ÝÀÀ
  • oxidase reaction
    »êÈ­ È¿¼Ò ¹ÝÀÀ
  • pain reaction
    µ¿Åë ¹ÝÀÀ
  • panic reaction
    °øÈ² ¹ÝÀÀ
    ±ØµµÀÇ ¶Ç´Â ºÒÇÕ¸®ÇÑ °øÆ÷¿Í ºÒ¾È µîÀÇ ¹ÝÀÀÀ» º¸ÀÌ´Â °Í.
  • periosteal reaction
    °ñ¸· ¹ÝÀÀ
  • peritectic reaction
    Æ÷Á¤ ¹ÝÀÀ
    ÇÕ±ÝÀ» ¿ëÀ¶ »óÅ¿¡¼­ ³Ã°¢ÇÒ ¶§, ÃÊÁ¤°ú ³ª¸ÓÁö ¾×»óÀÌ ¹ÝÀÀÇÏ¿© »õ·Î¿î °í»óÀ» Çü¼ºÇÏ´Â ¹ÝÀÀ.
  • photoallergic reaction
    ±¤¾Ë·¹¸£±â ¹ÝÀÀ
  • photodynamic reaction
    ±¤¿ªÇÐ ¹ÝÀÀ
  • potosensitivity reaction
    ±¤¼± °ú¹ÎÁõ ¹ÝÀÀ
  • psychogenic reaction
    ½ÉÀμº ¹ÝÀÀ
  • psychotic depressive reaction
    Á¤½Åº´Àû ¿ì¿ïÁõ, Á¤½Åº´¼º ¿ì¿ï ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
myosin heavy chain <protein> See myosin: do not confuse with heavy meromyosin which is a subfragment of the heavy chain of myosin II.
(18 Nov 1997)
myosin light chain <protein> The light chains of the muscle protein myosin. Each molecule of myosin is composed of two heavy chains and two pairs of light chains. The light chains have a molecular weight of about 20 kD and there is one dissimilar pair of light chains associated with each heavy chain.
The proteins all have sequence homology to calmodulin, but not all with calcium binding activity.
Several types are known: regulatory light chains (LC 2, DNTB light chains) probably regulate the ATPase activity of the heavy chain directly (through the binding of calcium) or indirectly (activating when they themselves are phosphorylated by myosin light chain kinase) and essential light chains (LC 1, LC 3, alkali light chains), which have a more subtle and apparently nonessential role.
In molluscan muscle the EDTA light chains (similar to LC 2 from vertebrate muscle) confer calcium sensitivity on the myosin itself.
The light chains are "calmodulin-like" proteins that bind calcium. Two of them can be removed easily, and two with difficulty. The light chains bind the heavy chains in the vicinity of the head groups of the myosin.
(12 Dec 1998)
myosin light chain kinase <enzyme> An enzyme that phosphorylates myosin light chains in the presence of ATP to yield myosin-light chain phosphate and ADP, and requires calcium and calmodulin.
The 20-kD light chain is phosphorylated more rapidly than any other acceptor, but light chains from other myosins and myosin itself can act as acceptors. The enzyme plays a central role in the regulation of smooth muscle contraction.
Chemical name: ATP:myosin-light-chain O-phosphotransferase
Registry number: EC 2.7.1.117
(12 Dec 1998)
haemolytic chain The haemolysis that occurs when complement is activated by the previously formed union of erythrocytes and specific antibody.
(05 Mar 2000)
H chain <protein> Heavy chain of immunoglobulin, see IgG, IgM, etc.
(18 Nov 1997)
heavy chain <protein> In general, the larger polypeptide in a multimeric protein. Thus the immunoglobulin heavy chain is of 50 kD, the light chain of 22 kD, whereas in myosin the heavy chain is very much larger (220 kD) than the light chains (~20 kD).
(18 Nov 1997)
heavy chain disease A disorder of immunoglobulin synthesis in which large quantities of abnormal heavy chains are excreted in the urine. The amino acid sequences of the n- (amino-) terminal regions of these chains are normal, but they have a deletion extending from part of the variable domain through the first domain of the constant region, so that they cannot form cross-links to the light chains. The defect arises through faulty coupling of the variable (v) and constant (c) region genes.
(12 Dec 1998)
xenobiotic medium chain fatty acid - coenzyme A ligase <enzyme> Partial amino acid sequence of enzyme from bovine liver mitochondria given I first source; has high sequence homology to human and rat sa protein
Registry number: EC 6.2.1.-
Synonym: xl-i ligase, xl-i carboxylic acid - CoA ligase
(26 Jun 1999)
short chain In bacteriology, a string of two to eight cells.
(05 Mar 2000)
short-chain acyl-CoA dehydrogenase See: acyl-CoA dehydrogenase (NADPH+).
(05 Mar 2000)
short-chain beta-hydroxyacyl-CoA dehydrase <enzyme> Forms trans-2-enoyl-CoA; maximal activity with trans-2-hexenoyl-CoA, followed by crotonyl-CoA; not the same as EC 4.2.1.17
Registry number: EC 4.2.1.-
Synonym: beta-hydroxybutyryl-CoA dehydrase, short-chain beta-hydroxyacyl-coenzyme a dehydrase
(26 Jun 1999)
side chain A chain of noncyclic atoms linked to a benzene ring, or to any cyclic chain compound, the atoms of an alpha-amino acid other than the alpha-carboxyl group, the alpha-amino group, the alpha-carbon, and the hydrogen attached to the alpha-carbon.
(05 Mar 2000)
side-chain theory Ehrlich postulated that cells contained surface extensions or side chains (haptophores) that bind to the antigenic determinants of a toxin (toxophores); after a cell is stimulated, the haptophores are released into the circulation and become the antibodies.
See: receptor.
Synonym: Ehrlich's postulate.
(05 Mar 2000)
nuclear chain fibre The shortest and most numerous type of intrafusal muscle fibre's in a neuromuscular spindle, containing a single row of centrally positioned nuclei.
(05 Mar 2000)
delta chain See: immunoglobulin. The heavy chains of mouse and human IgD immunoglobulins.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á